{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:09:02Z","timestamp":1785550142182,"version":"3.56.0"},"reference-count":114,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2023,10,3]]},"DOI":"10.1080\/17512433.2023.2251387","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T03:08:33Z","timestamp":1692846513000},"page":"939-957","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection"],"prefix":"10.1080","volume":"16","author":[{"given":"Emmanuella Chinonso","family":"Osuala","sequence":"first","affiliation":[{"name":"Center for the AIDS Program of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa"},{"name":"Discipline of Pharmacology, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Center for the AIDS Program of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E","family":"Dooley","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kogieleum","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Center for the AIDS Program of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa"},{"name":"MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubeshan","family":"Perumal","sequence":"additional","affiliation":[{"name":"Center for the AIDS Program of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa"},{"name":"MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"e_1_3_4_3_1","volume-title":"Fact sheet\u2014latest global and regional statistics on the status of the HIV epidemic","author":"UNAIDS. HIV\/AIDS","year":"2022","unstructured":"UNAIDS. HIV\/AIDS. Fact sheet\u2014latest global and regional statistics on the status of the HIV epidemic. Geneva: Joint United Nations Programme on HIV\/AIDS; 2022."},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60658-4"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0201-6"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005146"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v14i3.25"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/2325958220919231"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.05.012"},{"issue":"9","key":"e_1_3_4_10_1","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","article-title":"Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials","volume":"33","author":"Gupta SK","year":"2019","unstructured":"Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS (London, England). 2019;33(9):1455.","journal-title":"AIDS (London, England)"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60616-X"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1712-z"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000248"},{"issue":"3","key":"e_1_3_4_14_1","first-page":"31S","article-title":"Treatment guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents: an update","volume":"33","author":"Gibert CL","year":"2016","unstructured":"Gibert CL. Treatment guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents: an update. Fed Pract. 2016;33(Suppl 3):31S.","journal-title":"Fed Pract"},{"key":"e_1_3_4_15_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray AS","year":"2016","unstructured":"Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res. 2016;125:63\u201370.","journal-title":"Antiviral Res"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1898-1906.2005"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.045526"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001744"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000225"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00968-06"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25702"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4853"},{"issue":"19","key":"e_1_3_4_23_1","first-page":"7","article-title":"Policy brief: Update of recommendations on first-and second-line antiretroviral regimens","author":"World Health Organization.","year":"2019","unstructured":"World Health Organization. Policy brief: Update of recommendations on first-and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019;(WHO\/CDS\/HIV\/19.15): 7\u20138.","journal-title":"Geneva, Switzerland: World Health Organization"},{"key":"e_1_3_4_24_1","unstructured":"Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Department Of Health And Human Services. [cited 2023 Jul 14]. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/pediatric-arv\/tenofovir-af"},{"key":"e_1_3_4_25_1","first-page":"(11\/12):10","article-title":"Responses to Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin: HIV i-Base","volume":"18","author":"Clayden P","year":"2018","unstructured":"Clayden P. Responses to Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin: HIV i-Base. HIV Treatment Bulletin. 2018;18:(11\/12):10\u201311.","journal-title":"HIV Treatment Bulletin"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01152-15"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2767"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01151-15"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.19080\/IJOPRS.2018.02.555600"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182965d45"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt532"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001350"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000940"},{"issue":"11","key":"e_1_3_4_34_1","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/QAD.0000000000001817","article-title":"A week-48 randomized phase-3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive HIV-1 patients","volume":"32","author":"Eron JJ","year":"2018","unstructured":"Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS (London, England). 2018;32(11):1431.","journal-title":"AIDS (London, England)"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002463"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902824"},{"issue":"10107","key":"e_1_3_4_37_1","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax PE","year":"2017","unstructured":"Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073\u20132082.","journal-title":"Lancet"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00348-5"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2017.0203"},{"issue":"4","key":"e_1_3_4_40_1","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/S2352-3018(16)00024-2","article-title":"Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial","volume":"3","author":"Gallant JE","year":"2016","unstructured":"Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3(4):e158\u2013e65.","journal-title":"Lancet HIV"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001344"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30031-0"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12664"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30179-0"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104543"},{"issue":"6","key":"e_1_3_4_46_1","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","article-title":"Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Stellbrink H-J","year":"2019","unstructured":"Stellbrink H-J, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e364\u2013e72.","journal-title":"Lancet HIV"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30099-0"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30077-3"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30241-1"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30032-2"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/2047487315579291"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437741.48606.98"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110711"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402269"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202614"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31065-5"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00071-0"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506273"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2017.01.010"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280b07b33"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000908"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001186"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.2168"},{"key":"e_1_3_4_68_1","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","author":"Brown T","year":"2017","unstructured":"Brown T, Yin MT, Gupta S, et al. editors. Switching from TDF to TAF in HIV-infected adults with low BMD: a pooled analysis. Conference on Retroviruses and Opportunistic Infections (CROI). Seattle; 2017."},{"key":"e_1_3_4_69_1","volume-title":"European AIDS Conference","author":"Post F","year":"2017","unstructured":"Post F, Orkin C, Raffi F, et al. editors. Predictors of changes in bone mineral density and proteinuria from 5 randomized TDF-to-TAF switch studies: pooled analysis. European AIDS Conference; Milan, Italy: 2017."},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ296"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp462"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833ad8b4"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz472"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac949"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000680"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002930"},{"key":"e_1_3_4_78_1","first-page":"170","volume-title":"Journal of the international AIDS society","author":"Natukunda E","year":"2020","unstructured":"Natukunda E, Liberty A, Strehlau R, et al. Safety, pharmacokinetics and efficacy of low-dose E\/C\/F\/TAF in virologically suppressed children\u2265 2 years old living with HIV. In: editors. Journal of the international AIDS society. Southern Gate, Chichester: John Wiley & Sons Ltd the Atrium; 2020. p. 170\u2013171."},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(17)30009-3"},{"key":"e_1_3_4_81_1","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","author":"Rodriguez C","year":"2020","unstructured":"Rodriguez C, Chokephaibulkit K, Liberty A, et al. editors. Safety, PK, and efficacy of low dose B\/F\/TAF in children\u2265 2 years old living with HIV. Conference on Retroviruses and Opportunistic Infections (CROI). Boston; 2020."},{"key":"e_1_3_4_82_1","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Chen JS","year":"2018","unstructured":"Chen JS, Saez-Llorens A, Casta\u00f1o E, et al. Melvin A, editor. Safety, pharmacokinetics, and efficacy of FTC\/TAF in HIV-infected adolescen ts (12\u201318 years). Conference on Retroviruses and Opportunistic Infections. Boston; 2018."},{"key":"e_1_3_4_83_1","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","author":"Mujuru H","year":"2023","unstructured":"Mujuru H, Strehlau R, Kosalaraksa P, et al. Six-Month Outcome of F\/TAF Cobicistat-Boosted Darunavir in Children 14 to < 25 kg.Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, Washington; 2023."},{"key":"e_1_3_4_84_1","first-page":"00","article-title":"Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States the information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations","volume":"12","author":"Newborn A","year":"2021","unstructured":"Newborn A. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States the information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations. Management. 2021;12:00.","journal-title":"Management"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002767"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002944"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2020.1738384"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1010"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00314-7"},{"key":"e_1_3_4_90_1","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","author":"Chinula L","year":"2022","unstructured":"Chinula L, Goldberg E, Ziemba L, et al. Pregnancy Hemoglobin A1c and Glucose with DTG vs EFV, TDF vs TAF: IMPAACT 2010.Conference on Retroviruses and Opportunistic Infections (CROI). Colorado; 2022."},{"key":"e_1_3_4_91_1","volume-title":"Risk-benefit Trade-off for Pregnancy and Infant Outcomes: DTG, EFV, TAF, AND TDF. Conference on Retroviruses and Opportunistic Infections (CROI)","author":"Brummel S","year":"2022","unstructured":"Brummel S, Ziemba L, Coletti A, et al. editors. Risk-benefit Trade-off for Pregnancy and Infant Outcomes: DTG, EFV, TAF, AND TDF. Conference on Retroviruses and Opportunistic Infections (CROI); Virtual; 2022."},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00061-9"},{"issue":"1","key":"e_1_3_4_93_1","first-page":"6","article-title":"Pregnancy outcomes in pregnant women with HIV on tenofovir disoproxil fumarate (TDF) compared to tenofovir alafenamide (TAF)","volume":"4","author":"Thimm MA","year":"2022","unstructured":"Thimm MA, Livingston A, Ramroop R, et al. Pregnancy outcomes in pregnant women with HIV on tenofovir disoproxil fumarate (TDF) compared to tenofovir alafenamide (TAF). Journal Of AIDS And HIV Treatment. 2022;4(1):6.","journal-title":"Journal Of AIDS And HIV Treatment"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002880"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10235-1"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001217"},{"key":"e_1_3_4_98_1","first-page":"S78","article-title":"Tenofovir (TFV) or tenofovir alafenamide (TAF) concentration in breast milk and infants\u2019 cord blood, with tenofovir disoproxil fumarate (TDF) or TAF treatment in pregnancy","volume":"14","author":"Li B","year":"2020","unstructured":"Li B, Gu Y, Wang Y. Tenofovir (TFV) or tenofovir alafenamide (TAF) concentration in breast milk and infants\u2019 cord blood, with tenofovir disoproxil fumarate (TDF) or TAF treatment in pregnancy. Hepatol Int. 2020;14:S78.","journal-title":"Hepatol Int"},{"key":"e_1_3_4_99_1","unstructured":"Tuberculosis: fact sheet. [Internet]. 2022 [cited 2022 Nov 11]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1259066"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.680-684.2005"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001699"},{"key":"e_1_3_4_104_1","volume-title":"16th European AIDS Conference (EACS)","author":"Custodio J","year":"2017","unstructured":"Custodio J, West S, Lutz J, et al. Twice daily administration of tenofovir alafenamide in combination with rifampin: potential for tenofovir alafenamide use in HIV-TB coinfection. In Collins S, editor. 16th European AIDS Conference (EACS). Milan; 2017"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz068"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067765"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.09.1423"},{"key":"e_1_3_4_108_1","unstructured":"WHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment. 2020."},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033400"},{"key":"e_1_3_4_110_1","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Arora P","year":"2021","unstructured":"Arora P, Collins S, Martin H, et al. Drug interactions with once-daily B\/FTC\/TAF in combination with once-weekly rifapentine. Conference on Retroviruses and Opportunistic Infections. Mar 2021;Virtual. 2021."},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25844"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9172607"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30107-8"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30024-3"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30421-2"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.7326\/M19-3478"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.11.012"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30506-9"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2023.2251387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T08:00:48Z","timestamp":1697097648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2023.2251387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":114,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,3]]}},"alternative-id":["10.1080\/17512433.2023.2251387"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2023.2251387","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}